Stay updated on REGN728 Safety & Tolerability Clinical Trial

Sign up to get notified when there's something new on the REGN728 Safety & Tolerability Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the REGN728 Safety & Tolerability Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    Change Detected
    Summary
    The study has been updated to version v2.10.0, indicating a new release with potentially significant changes from the previous version v2.9.7.
    Difference
    0.7%
    Check dated 2024-07-23T14:33:28.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T06:24:03.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-07-02T14:45:44.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-27T10:36:39.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-26T09:32:01.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Revision: v2.9.0' has been updated to 'FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : Randomized Interventional Model : Single Group Assignment Masking : Double ( Participant Investigator ) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Cohort 1 Dose 1 versus placebo Biological : REGN728 2 Subcutaneous Cohorts (dose 1, 2) Experimental : Cohort 2 Dose 2 versus placebo Biological : REGN728 2 Subcutaneous Cohorts (dose 1, 2) Primary Outcome Measures Outcome Measure Measure Description Time Frame The primary endpoint in the study is the percentage of subjects with treatment emergent adverse events, reported from the administration of study drug on day 1 to the completion of the study on day 106. 106 days Revision: v2.9.1'. This change represents an update in the study details and primary outcome measures.
    Difference
    9%
    Check dated 2024-06-25T08:47:29.000Z thumbnail image

Stay in the know with updates to REGN728 Safety & Tolerability Clinical Trial

Enter your email address, and we'll notify you when there's something new on the REGN728 Safety & Tolerability Clinical Trial page.